RE:YOUTH (YONSEI BH Arterial Stemcell Clinic)
RE:YOUTH (YONSEI BH Arterial Stemcell Clinic)
République de Corée, Cheonan
La clinique est certifiée :
| République de Corée | Turquie | Espagne | |
| Thérapie par cellules souches pour la SLA (sclérose latérale amyotrophique) | - | de $30,000 | de $40,000 |
Bookimed ne facture pas de frais supplémentaires pour les prix des Thérapie par cellules souches pour la SLA (sclérose latérale amyotrophique). Les tarifs sont issus des listes de prix officielles des cliniques. Vous payez directement à la clinique lors de votre arrivée pour votre Thérapie par cellules souches pour la SLA (sclérose latérale amyotrophique).
Bookimed s'engage pour votre sécurité. Nous ne travaillons qu'avec des établissements médicaux qui respectent des normes internationales élevées dans Thérapie par cellules souches pour la SLA (sclérose latérale amyotrophique) et qui possèdent les licences nécessaires pour accueillir des patients internationaux dans le monde entier.
Bookimed offre une assistance experte gratuite. Un coordinateur médical personnel vous accompagne avant, pendant et après votre traitement, en résolvant tous les problèmes. Vous n'êtes jamais seul dans votre parcours de Thérapie par cellules souches pour la SLA (sclérose latérale amyotrophique).
Stem cell therapy for ALS in South Korea is considered biologically safe. The Korean Ministry of Food and Drug Safety approved Neuronata-R in 2014. Treatments use autologous mesenchymal stem cells from the patient's own bone marrow. This minimises risks like infection or immune rejection during cerebrospinal fluid delivery.
Bookimed Expert Insight: Highly specialised clinics like RE:YOUTH (YONSEI BH Arterial Stemcell Clinic) limit intake to two patients daily. This VIP approach allows intensive monitoring. Their arterial infusion technique is unique in Korea. It aims to deliver cells closer to the affected nerve tissues than standard injections.
Patient Consensus: Seeking treatment within regulated clinical frameworks is essential. Genuine programs use the patient's own cells. This reduces the risk of rejection. Patients find comfort in Korea's established medical laws. Professional oversight provides peace of mind during the process.
Stem cell therapy in South Korea slows ALS progression. It also improves survival rates for slow-progressing patients. Specialists use Neuronata-R, an approved autologous treatment, and arterial delivery. These methods focus on neuroprotection rather than a cure. Success is highest when treatment begins within 2 years of symptom onset.
Bookimed Expert Insight: South Korea's clinical landscape is unique because it offers arterial delivery through clinics like RE:YOUTH. This method sends cells directly to the brain. While most hospitals use spinal injections, only 2 patients daily receive this VIP-level arterial treatment in Cheonan. This boutique approach delivers high-intensity medical attention for complex neurological cases.
Patient Consensus: Patients in South Korea report that therapy works best when viewed as a way to slow decline. The consensus highlights that while it is not a cure, it offers functional improvement. Many find the structured clinical trials more reassuring than standard commercial packages.
Neuronata-R is South Korea's officially licensed stem cell therapy for ALS. The Ministry of Food and Drug Safety granted approval for this autologous mesenchymal stem cell treatment. It uses a patient's own bone marrow cells. This slows disease progression through neuroprotective and immune-modifying effects.
Bookimed Expert Insight: Neuronata-R is the primary regulated option. However, clinics in cities like Cheonan now perform direct arterial infusions. This approach targets systemic chronic inflammation. Bookimed data shows these facilities limit intake to two patients daily. This keeps safety standards high.
Patient Consensus: Patients travel to South Korea because the treatment follows formal research and regulatory pathways. Realistic expectations focus on slowing the decline of ALS. Patients do not expect a complete cure.
NeuroNata-R uses a patient's own bone marrow stem cells to slow ALS progression. It is a conditionally approved therapy in South Korea. The treatment releases neurotrophic factors and modulates immune responses. This protects existing motor neurons rather than replacing them in the spinal cord.
Bookimed Expert Insight: South Korea remains a key global hub for ALS regenerative medicine. Leading clinics like RE:YOUTH serve 1,000+ patients annually. These centres often specialise in rare disease care. They provide an approved pathway for NeuroNata-R. This pathway differs from purely experimental treatments elsewhere.
Patient Consensus: Seeking formally approved products in South Korea provides more confidence than unverified options. Most patients see this as a way to potentially slow progression. Realistic expectations are essential. It is not a cure but a regulated experimental step.
The treatment process involves a multi-stage protocol focused on neuroprotection. Specialists assess medical history remotely before harvesting Mesenchymal Stem Cells (MSCs). These cells are cultured in ministry-approved labs for several weeks. They are then delivered via intrathecal injection or direct arterial infusion. These methods bypass the blood-brain barrier.
Bookimed Expert Insight: Most clinics focus on lumbar punctures. However, centres like RE:YOUTH (YONSEI BH Arterial Stemcell Clinic) specialise in arterial infusions. They limit intake to 2 patients daily. This allows highly personalised cell delivery protocols for rare neurological conditions.
Patient Consensus: Dealing with clinics in South Korea feels organised even though most expect repeat sessions. Patients appreciate the early access to innovative therapies while staying grounded about experimental outcomes.
Patients in South Korea primarily receive autologous mesenchymal stem cells for ALS treatment through strictly regulated protocols. Clinics draw on sources like bone marrow, blood, or adipose tissue. However, the specific cell type is set by providers and trial guidelines, not patient preference.
Bookimed Expert Insight: While South Korea ranks second globally for medical requests, specialised ALS care is highly exclusive. RE:YOUTH clinic, for example, limits intake to only 2 patients daily. This maintains VIP-level attention. This exclusivity means the complex arterial infusion protocols are managed with high precision. Every individual receives this precise care.
Patient Consensus: Patients mention that South Korean clinics follow fixed protocols. They advise getting the exact cell source and administration route in writing. Many found that these treatments slow disease progression rather than cure it.